Publications by authors named "Lakshmi R Iyer"

During amoebiasis, colonization of the gut by Entamoeba histolytica can lead to alterations of the host microbiota. In this study, we have compared the gut microbiota of patients of amoebiasis with healthy controls using 16S rRNA gene variable regions, (V1-V3) and (V3-V5), of the bacterial genome. From this 16S rRNA gene amplicon data, one paired-end and two single-end datasets were selected and compared by the number of OTUs obtained, sequence count, and diversity analysis.

View Article and Find Full Text PDF

The protist parasite causes amoebiasis, a major public health problem in developing countries. Only a small fraction of patients infected with the parasite display invasive disease involving colon or extra intestinal tissues such as liver. exists as two distinct forms, cysts, the infective form, and trophozoites, that are responsible for disease pathology.

View Article and Find Full Text PDF

Kappa opioid receptor (KOR) is an important mediator of pain signaling and it is targeted for the treatment of various pains. Pharmacophore based mining of databases led to the identification of 2-aminobenzimidazole derivative as KOR agonists with selectivity over the other opioid receptors DOR and MOR. A short SAR exploration with the objective of identifying more polar and hence less brain penetrant agonists is described herewith.

View Article and Find Full Text PDF

Entamoeba histolytica infections are endemic in the Indian subcontinent. Five to eight percent of urban population residing under poor sanitary conditions suffers from Entamoeba infections. Metronidazole is the most widely prescribed drug used for amoebiasis.

View Article and Find Full Text PDF

Background: The major clinical manifestations of Entamoeba histolytica infection include amebic colitis and liver abscess. However the majority of infections remain asymptomatic. Earlier reports have shown that some E.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the selective inhibition of HDAC6 using Tubastatin, which shows promise in treating autoimmune and inflammatory diseases by modulating inflammatory cell functions.
  • Tubastatin effectively reduces pro-inflammatory cytokines TNF-α and IL-6 in macrophage models, demonstrating its potential as a therapeutic agent with minimal toxicity.
  • In animal models of inflammation and arthritis, Tubastatin significantly decreases disease symptoms and inflammatory markers, indicating its effectiveness compared to traditional treatments like dexamethasone.
View Article and Find Full Text PDF